From "Two-Trial Dogma" to the Single Pivotal Standard: The Evolution of FDA Evidence Requirements

The "two-trial" rule was born from the 1962 Kefauver-Harris Amendment to the Federal Food, Drug, and Cosmetic Act, which mandated that manufacturers prove a drug was not just safe, but also effective. This established the "substantial evidence" standard, which the FDA historically interpreted as requiring at least two adequate and well-controlled clinical trials. This "two-trial dogma" served as a statistical insurance policy: in a world where biologic understanding was more limited, requiring a developer to be "lucky twice" reduced the probability of a false-positive result from 250 in 10,000 to just 6 in 10,000.

However, as of 2026, the regulatory landscape has reached a historic turning point. Here is how the "substantial evidence" requirement evolved from a rigid duplication rule into a flexible, precision-based standard.

1. The 1998 Foundation: Establishing Statutory Flexibility

The first major shift toward modern flexibility arrived with the 1998 Guidance: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Following the FDA Modernization Act (FDAMA) of 1997, the agency gained formal statutory authority to grant marketing authorization based on a single adequate and well-controlled study combined with "confirmatory evidence".

While this allowed for disease-by-disease flexibility—particularly in oncology and rare diseases, where single trials began to support the majority of approvals—manufacturers remained confused about exactly when a single trial would be accepted. For most "Main Street" drugs or drugs for common diseases, the two-trial expectation remained the functional default.

2. The 2023 Expansion: Defining "Confirmatory Evidence"

In September 2023, the FDA released updated draft guidance "Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence" to clarify what constitutes "confirmatory evidence" when only one pivotal trial is conducted. This guidance acknowledged that modern drug development relies on both statistical and biologic inferences. Under this framework, a single trial could be bolstered by:

• Clinical Evidence from a Related Indication

• Mechanistic or Pharmacodynamic Evidence

• Evidence from Relevant Animal Model

• Evidence from Other Members of the Same Pharmacological Class

• Natural History Evidence

• Real-World Data/Evidence (RWD/RWE)

• Evidence from Expanded Access Use of an Investigational Drug

3. The 2026 Paradigm Shift: The New Default

Last week, in February 2026, the FDA officially ended the "two-trial dogma." In a landmark article "One Pivotal Trial, the New Default Option for FDA Approval - Ending the Two-Trial Dogma" in the New England Journal of Medicine, FDA officials announced that a one-trial requirement is now the agency's new default standard for drug approval. We are waiting for the formal FDA guidance to provide the details about this paradigm shift.

Why the shift?

• Precision and Biology: Modern drug discovery is increasingly precise. The FDA now considers biochemical changes and biomarkers that tell a "complete biologic story," making overreliance on a second trial unnecessary when the "mechanistic science is sound".

• Economic Relief: A single pivotal study can cost between $30 million and $150 million and take years to complete. By moving to a one-trial default, the FDA aims to lower capital costs and remove a primary justification for high drug prices.

• Quality Over Quantity: Officials argue that two trials can provide "false assurance" if their designs are deficient (e.g., substandard control arms or dubious endpoints). The agency will now focus its energy on ensuring the single required trial is "robust and sound".

The Guardrails: When Two Trials Are Still Required

The FDA will not abandon the two-trial standard entirely. Additional studies may still be required if:

• An intervention has a nebulous or nonspecific mechanism of action.

• The trial affects only a labile or short-term surrogate outcome.

• The primary trial has underlying limitations or deficiencies.

Conclusion

We have moved from an era of Replication (the 1962-1998 standard) to Precision (the 2026 default). By formally changing the "default option," the FDA expects to spur a surge in biomedical innovation and speed life-saving drugs to the patients.

Additional Reading:

• raps.org Experts react to FDA’s shift to single pivotal trials for most drugs
• fda.gov (2016) Promoting Safety and Effective Drugs for 100 years
• Sasinowski et al (2012) Quantum of Effectiveness EVidence in FDA's Approval of Orphan Drugs
• Sasinowski et al (2015) Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs: Update, July 2010 to June 2014

The Statistical Magic Trick: How Trials Share Results While Staying Blind

 

In the world of clinical research, "breaking the blind" is typically a cardinal sin. Yet, high-stakes Phase 3 trials like ORIGIN 3 (atacicept), PROTECT (sparsentan), and ATTRIBUTE-CM (acoramidis) have all successfully navigated the complex path of publishing interim results in the New England Journal of Medicine while keeping their long-term studies scientifically intact.

• Lafayette et al (2026) A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
• Perkovic et al (2026) Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
• Gillmore, et al (2024)Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy and its attached protocol and statistical analysis plan "

How do they pull off this statistical magic trick? It comes down to a rigorous architectural separation of data and people including statistical analysis team. Here is a look at the techniques used to maintain the "blind" during interim disclosures.

1. The "Firewall" Strategy: Independent Reporting Teams

The most critical technique used across all three studies is the creation of a "Firewall."

While a trial is ongoing, the people running the study (Sponsor clinical teams, investigators at hospitals, and the patients) must remain blinded. To perform an interim analysis, the Sponsor appoints an Independent Reporting Team (IRT) or an Independent Statistical Center.

• How it works: This group has no contact with the study sites. They receive the raw "unblinded" data, perform the calculations for the primary endpoint (like the 36-week proteinuria reduction in PROTECT or ORIGIN 3), and prepare the manuscript for publication.
• The Result: The people actually treating the patients remain in the dark, ensuring their medical decisions aren't influenced by knowing who is on the "winning" drug.

2. Safeguarding Against "Functional Unblinding"

In some trials, the drug’s effect is so obvious it could accidentally reveal the treatment.

• In ORIGIN 3: Atacicept significantly lowers serum IgA and IgG levels. If a doctor saw these lab results, they would immediately know the patient was on the active drug. To prevent this, these specific lab values are suppressed. The results are sent to the Independent Reporting Team but are hidden from the investigators and the Sponsor’s site monitors.
• In PROTECT: This study compared two active drugs (sparsentan vs. irbesartan). To ensure the difference in pill appearance didn't tip anyone off, they used a Double-Dummy design. Every patient took two sets of pills—one active and one placebo—so the physical routine remained identical for everyone.

3. Aggregate vs. Individual Disclosure

A common misconception is that "publishing the results" means everyone knows who got what. In reality, the NEJM publications for these trials only disclose aggregate data (group averages), not the individual patient level data.

• In ATTRIBUTE-CM: When the Part A results (12-month 6-minute walk distance) were disclosed, the public learned how the group performed. However, the individual treatment assignments for each patient remained locked in the secure database.
• The Benefit: Even if an investigator reads the NEJM article and sees that acoramidis is effective, they still do not know if the specific patient sitting in their office is receiving acoramidis or the placebo.

4. Prespecified Alpha Spending and "The Gatekeeper"

To maintain the statistical integrity of the final results (like the 104-week kidney function in ORIGIN 3 or the 30-month clinical outcomes in ATTRIBUTE-CM), the Statistical Analysis Plan (SAP) dictates exactly how much "statistical credit" is used during the interim look.

• The Independent Data Monitoring Committee (iDMC) acts as the gatekeeper. They review the unblinded data behind closed doors and only allow the trial to proceed if the interim disclosure doesn't compromise the "power" of the final analysis.

Why go through all this trouble?

The goal is Accelerated Approval. By using these techniques, sponsors can show the FDA (and the medical community) that a drug works on a "surrogate marker" (like proteinuria) at an interim stage. This allows life-saving drugs to reach patients years earlier, while the "blinded" portion of the trial continues to gather the long-term data needed for full, traditional approval.

By combining physical dummies, suppressed lab data, and strict "firewalls" between statistical teams, researchers prove that you can indeed share the news of a trial's success without ruining the science that supports it.

Some Extra Words on ATTRIBUTE-CM Study

ATTRIBUTE-CM study is a phase 3, double-blind trial, 632 patients with transthyretin amyloid cardiomyopathy were randomly assigned in a 2:1 ratio to receive acoramidis hydrochloride at a dose of 800 mg twice daily or matching placebo for 30 months. The study contained two parts: Part A with primary endpoint of change from baseline to Month 12 of treatment in distance walked during the 6MWT, Part B with primary endpoint of a hierarchical combination of All-Cause mortality and CV-related hospitalization over a 30month period.

There were two readouts for the study and the Part A readouts were based on an interim analyses by the independent DMC. 

In December 2021, BridgeBio Pharma experienced a major setback when its Phase 3 ATTRibute-CM trial for acoramidis (a treatment for transthyretin amyloid cardiomyopathy - ATTR-CM) failed to meet its primary endpoint of improving the 6-minute walk distance (6MWD) at Month 12 (Part A primary efficacy endpoint). In the initial 12-month data, patients taking acoramidis did not show a statistically significant improvement in their 6MWD compared to those on a placebo.

Despite the failure of the 6MWD endpoint at 12 months, the study continued because the independent data monitoring committee noted encouraging trends in other areas. By July 2023, BridgeBio reported positive top-line results from the full study (Month 30), where acoramidis demonstrated a highly statistically significant improvement in a hierarchical analysis that included mortality, hospitalization, and 6MWD (Part B primary efficacy endpoint). 

Following the successful long-term data (Part B), which showed a 25% reduction in all-cause mortality and 50% reduction in cardiovascular hospitalization frequency (known as Attruby), the drug was approved by the FDA, with 3,751 prescriptions filled as of August 2025.

The study included an embedded Part A readouts that required the unblinding for interim analysis. The sponsor specified the following for maintaining the blinding for the overall study while the Part A results were analyzed and disclosed.